Osimertinib in Resected EGFR-Mutated NSCLC

被引：1
|
作者：
Tsuboi, Masahiro [1 ]
Herbst, Roy S. [2 ]
Wu, Yi-Long [3 ]
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Japan
[2] Yale Canc Ctr, New Haven, CT 06510 USA
[3] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2023年 / 389卷 / 14期
关键词：
D O I：
10.1056/NEJMc2309385
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
To the Editor: The results of the final analysis of the ADAURA trial, reported by Tsuboi et al. (July 13 issue),(1) show a relevant benefit in overall survival among patients with resected non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation who received adjuvant osimertinib. It is disappointing that less than half of the patients in the control group who had a relapse actually received osimertinib as the first subsequent treatment. The authors explain that this was due to the double-blind design, because the amendment allowing open-label osimertinib was implemented only after the primary analysis. Thus, many patients . . .
引用
收藏
页码：1341 / 1342
页数：2
相关论文
共 50 条
  • [11] Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
    Wu, Yi-Long
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Kim, Sang-We
    Kato, Terufumi
    Laktionov, Konstantin
    Vu, Huu Vinh
    Wang, Zhijie
    Lu, Shun
    Lee, Kye Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Atasoy, Ajlan
    Herbst, Roy S.
    Tsuboi, Masahiro
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (03) : 423 - 433
  • [12] Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib
    Belani, Neel
    Rizwan, Farsha
    Hasler, Jill
    Bauman, Jessica
    Mitchell, Khadijah
    Borghaei, Hossein
    Bodor, Joseph N.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [13] Osimertinib in Stage III EGFR-Mutated NSCLC - Game, Set, Match
    Leighl, Natasha B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (07): : 652 - 654
  • [14] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Tsuboi, Masahiro
    He, Jie
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Kato, Terufumi
    Vu, Huu-Vinh
    Lu, Shun
    Lee, Kye-Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Hodge, Rachel
    Atasoy, Ajlan
    Rukazenkov, Yuri
    Herbst, Roy S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1711 - 1723
  • [15] Osimertinib in EGFR-Mutated Lung Cancer
    Liang, Wenhua
    Zhong, Ran
    He, Jianxing
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 675 - 675
  • [16] Patient Reports from ADAURA: HRQol Data on Osimertinib as adjuvant Therapy in Patients with resected EGFR-mutated (EGFRm) NSCLC
    Engel-Riedel, W.
    Majem, M.
    Goldman, J. W.
    Grohe, C.
    John, T.
    Laktionov, K.
    Kim, S.
    Kato, T.
    Vu, H. V.
    Lu, S.
    Lee, K.
    Akewanlop, C.
    Yu, C. J.
    de Marinis, F.
    Bonanno, L.
    Domine, M.
    Shepherd, F. A.
    Zeng, L.
    Kulkarni, D.
    Medic, N.
    Tsuboi, M.
    Herbst, R. S.
    Wu, Y. L.
    Wohlleber, M.
    [J]. PNEUMOLOGIE, 2021, 75 : S21 - S21
  • [17] Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
    Mei-Mei Zheng
    Yang-Si Li
    Hai-Yan Tu
    Hao Sun
    Kai Yin
    Ben-Yuan Jiang
    Jin-Ji Yang
    Xu-Chao Zhang
    Qing Zhou
    Chong-Rui Xu
    Zhen Wang
    Hua-Jun Chen
    De-Xiang Zhou
    Yi-Long Wu
    [J]. BMC Medicine, 20
  • [18] Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
    Zheng, Mei-Mei
    Li, Yang-Si
    Tu, Hai-Yan
    Sun, Hao
    Yin, Kai
    Jiang, Ben-Yuan
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Zhou, Qing
    Xu, Chong-Rui
    Wang, Zhen
    Chen, Hua-Jun
    Zhou, De-Xiang
    Wu, Yi-Long
    [J]. BMC MEDICINE, 2022, 20 (01)
  • [19] Postoperative Chemotherapy-Use and Results of the ADAURA-Study: Osimertinib as adjuvant Therapy in resected EGFR-mutated NSCLC Patients
    Grohe, C.
    Wu, Y. L.
    John, T.
    Majem, M.
    Goldman, J. W.
    Kim, S.
    Kato, T.
    Laktionov, K.
    Vu, H. V.
    Wang, Z.
    Lu, S.
    Lee, K.
    Akewanlop, C.
    Yu, C. J.
    De Marinis, F.
    Bonanno, L.
    Domine, M.
    Shepherd, F. A.
    Zeng, L.
    Atasoy, A.
    Herbst, R. S.
    Tsuboi, M.
    Engel-Riedel, W.
    [J]. PNEUMOLOGIE, 2021, 75 : S18 - S19
  • [20] Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
    Crowley, Fionnuala
    Fitzgerald, Bailey G.
    Bhardwaj, Aarti S.
    Siraj, Irine
    Smith, Cardinale
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (01):
12345